Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs. 75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP) Strand, V., Kremer, J. M., Li, Z. G., Hall, S., Fleischmann, R. M., Genovese, M. C., Martin-Mola, E., Isaacs, J., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S. H., Koncz, T., Riese, R., Bradley, J. D. WILEY-BLACKWELL. 2011: S1032–S1032
View details for Web of Science ID 000297621503206